About 2 results found for searched term "Vidofludimus" (0.18 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M4876 | Vidofludimus | DHODH |
| SC12267, 4SC-101 | ||
| Vidofludimus(4SC-101; SC12267) is an immunosuppressant that inhibits DHODH and inhibits il-17 secretion without affecting lymphocyte proliferation. | ||
| M28227 | Vidofludimus hemicalcium | DHODH |
| 4sc-101 hemicalcium; SC12267 hemicalcium | ||
| Vidofludimus (4sc-101; SC12267) hemicalcium is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus hemicalcium, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus hemicalcium also can be used for the research of fatty liver by targeting FXR. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
